6511-88-2

Basic information

• Product Name: Piperazine, 1-(trifluoroacetyl)- (7CI,8CI,9CI)
• Synonyms: Piperazine, 1-(trifluoroacetyl)- (7CI,8CI,9CI);1-(2,2,2-Trifluoroacetyl)piperazine;1-(Trifluoroacetyl)piperazine;2,2,2-Trifluoro-1-piperazin-1-ylethanone
• CAS NO: 6511-88-2
• Molecular Formula: C₆H₉F₃N₂O
• Molecular Weight: 182.1436696
• Product Categories: ACETYLHALIDE
• Mol File: 6511-88-2.mol

Chemical Properties

• Melting Point: 32℃
• Boiling Point: 273℃
• Flash Point: 119℃
• Appearance: /
• Density: 1.290
• Vapor Pressure: 0.00585mmHg at 25°C
• Refractive Index: 1.41
• PKA: 7.83±0.10(Predicted)
• CAS DataBase Reference: Piperazine, 1-(trifluoroacetyl)- (7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(trifluoroacetyl)- (7CI,8CI,9CI)(6511-88-2)
• EPA Substance Registry System: Piperazine, 1-(trifluoroacetyl)- (7CI,8CI,9CI)(6511-88-2)

Safety Data

• Hazardous Substances Data: 6511-88-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H9F3N2O/c7-6(8,9)5(12)11-3-1-10-2-4-11/h10H,1-4H2

Upstream product

• 110-85-0 piperazine 
• 383-63-1 ethyl trifluoroacetate, 
• 77278-37-6 4-(2,2,2-trifluoroacetyl)piperazine-1-carboxylic acid tert-butyl ester 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 1252779-85-3 1-[4-(1-benzhydrylazetidin-3-yl)piperazin-1-yl]-2,2,2-trifluoroethanone 
• 1541185-10-7 2,2,2-trifluoro-1-(4-{5-[4-(2H-pyrazol-3-yl)phenoxy]-1H-benzoimidazol-2-ylmethyl}piperazin-1-yl)ethanone 
• 1252765-77-7 2,2,2-trifluoro-1-(4-(1-(1-(4-fluorophenyl)-1H-indole-5-carbonyl)azetidin-3-yl)piperazin-1-yl)ethanone 
• 1393482-25-1 8-(4-fluoro-3-{[4-(trifluoroacetyl)piperazin-1-yl]carbonyl}benzyl)-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one 
• 1260098-31-4 2,2,2-trifluoro-1-[4-(2-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2-oxo-ethyl)-piperazin-1-yl]-ethanone 
• 1391636-30-8 C₁₇H₂₀ClF₃N₂O₃ 
• 1196669-73-4 C₃₁H₃₁F₃N₆O₂S 
• 878805-35-7 t-butyl ((1S)-1-{3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}ethyl)carbamate 
• 878805-12-0 t-butyl ((1S)-1-{4-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}ethyl)carbamate 

Relevant articles and documents

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

The present disclosure provides modified oligonucleotides and compositions and methods thereof. In some embodiments, provided technologies comprise modified sugars and/or modified internucleotidic linkages. In some embodiments, the present disclosure provides technologies for preparing modified oligonucleotides. In some embodiments, the present disclosure provides chirally controlled oligonucleotide compositions and methods for their preparation and uses.

N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

MONOACYLGLYCEROL LIPASE INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES AND RELATED DISORDERS

Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.

Substituted phenoxypropyl-(R)-2-methylpyrrolidine aminomethyl ketones as histamine-3 receptor inverse agonists

Optimization of a series of aminomethyl ketone diamine H3R antagonists to reduce the brain exposure by lowering the pKa, led to molecules with improved pharmacokinetic properties. Compounds 9, 19, and 25 had high affinity for human H3R and demonstrated in vivo H3R functional activity in the rat dipsogenia model. Compound 9 displayed modest wake-promoting activity in the rat EEG/EMG model.

AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I), wherein Y, Z, R1, and s are defined herein.

HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I), wherein Y, r, R2 and Z are defined here

Molecular features of the prazosin molecule required for activation of Transport-P

Closely related structural analogues of prazosin have been synthesised and tested for inhibition and activation of Transport-P in order to identify the structural features of the prazosin molecule that appear to be necessary for activation of Transport-P. So far, all the compounds tested are less active than prazosin. It is shown that the structure of prazosin appears to be very specific for the activation. Only quinazolines have been found to activate, and the presence of the 6,7-dimethoxy and 4-amino groups appears to be critically important.

Ethyl trifluoroacetate: A powerful reagent for differentiating amino groups

Selective protection of primary amines in the presence of secondary amines and monofunctionalization of symmetric primary and secondary diamines using ethyl trifluoroacetate is described. Effective differentiation of primary, secondary and tertiary alkyl-substituted primary amines from one another by ethyl trifluoroacetate acylation is also demonstrated. These results are explained on the basis of steric and electronic effects of the substrate amines.